In our study, a monoclonal antibody against GAP43 (mAb GAP43) was modified on the surface of drug-loaded exosomes to target impaired neurons with a high expression of GAP43 in the ischemic penumbra to improve cerebral ischemia therapy. The gene discussed is GAP43; the disease is Cerebral ischemia.